Close the acquisition of TEMBEXA rights from Chimerix

Delivered after the deadline (88 days after the deadline)

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 16 May 2022
Due: 30 Jun 2022
Delivered: 26 Sep 2022

Deadline
Met
Late
Not met
Today

What the company said

“Subject to the satisfaction or waiver of the closing conditions, the companies expect the transaction to close as early as the end of the second quarter of 2022.”

SourceEmergent BioSolutions Inc. Form 8-K press release, 2022-05-16
FilingSEC filing index
Deadline as statedthe end of the second quarter of 2022
Deadline used30 Jun 2022, the last day of the stated period
TypeTransaction
Permanent referenceKI-C-2022-EBS-002475
Cite as https://keptindex.org/c/KI-C-2022-EBS-002475/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company expected to close the acquisition by the end of Q2 2022, but the transaction was not completed until September 26, 2022.

A
Emergent BioSolutions Inc. 10-Q filed 2022-08-02 Regulatory filing · published 2 Aug 2022 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint affafdef772d
“Closing of the Transaction is currently expected to occur during the third quarter of 2022.” ✓ confirmed on the page
A
Emergent BioSolutions Inc. 10-K filed 2023-03-01 Regulatory filing · published 1 Mar 2023 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 3f0100dba99a
“On September 26, 2022, we acquired exclusive worldwide rights to brincidofovir from Chimerix Inc.” ✓ confirmed on the page

Market reaction: the shares moved -5.2% against the S&P 500 over the three sessions around the disclosure (1 Aug 2022 to 4 Aug 2022). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +92 days
2 versions

Version 1 · original · stated 16 May 2022

Deadline 30 Jun 2022 (“the end of the second quarter of 2022”) · wording expected
Version 2 · stated 1 Aug 2022

Deadline 30 Sep 2022 (“Q3 2022”) · wording expected

“continue to anticipate transaction closing in Q3 2022”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Acquisition close
Indicative materiality: High rules
Action: Close
Deliverable: Acquisition of TEMBEXA rights
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High
Conditional: Yes: satisfaction or waiver of the closing conditions; expiration or early termination of the applicable waiting period under the HSR Act; execution of an anticipated procurement contract between Chimerix and BARDA; receipt of any required consent from BARDA to a pre-novation agreement
Depends on: Regulatory, Government, Partner

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.